Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abbott Laboratories : Gets FDA Clearance for Portico with FlexNav Transcatheter Aortic Valve Replacement

09/20/2021 | 11:00am EDT


© MT Newswires 2021
All news about ABBOTT LABORATORIES
05:35pDow Jones Industrial Average : Strong earnings reports lift Wall Street
RE
04:21pBrinker, Baker Hughes fall; Anthem, Abbott Laboratories rise
AQ
03:52pHealth Care Stocks Rally for Second Consecutive Day
MT
11:39aGLOBAL MARKETS LIVE : Kering, Netflix, Roche, United Airlines, Xiaomi...
11:12aAbbott raises annual earnings outlook as COVID-19 test sales rebound
RE
09:42aABBOTT LABORATORIES : Third-Quarter Results Beat Views With Revenue Getting COVID-19 Test ..
MT
09:41aWALL STREET STOCK EXCHANGE : Earnings season, bitcoin and the metaverse
09:14aHealth Care Stocks Advance Pre-Bell Wednesday
MT
08:03aAbbott Raises Full-Year Earnings Guidance
DJ
08:00aABBOTT LABORATORIES : Q3 Adjusted Earnings, Net Sales Rise; 2021 Earnings Per Share Guidan..
MT
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
Financials (USD)
Sales 2021 40 661 M - -
Net income 2021 6 141 M - -
Net Debt 2021 10 684 M - -
P/E ratio 2021 31,3x
Yield 2021 1,39%
Capitalization 219 B 219 B -
EV / Sales 2021 5,64x
EV / Sales 2022 5,65x
Nbr of Employees 109 000
Free-Float 88,8%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | MarketScreener
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 123,31 $
Average target price 131,90 $
Spread / Average Target 6,97%
EPS Revisions
Managers and Directors
Robert B. Ford President, CEO, Chief Operating Officer & Director
Robert Emmett Funck Chief Financial Officer & Executive VP-Finance
Miles D. White Executive Chairman
Sabina Ewing Chief Investment Officer, VP-Business & Technology
Roxanne Schuh Austin Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABBOTT LABORATORIES12.62%211 568
MEDTRONIC PLC3.97%164 458
BECTON, DICKINSON AND COMPANY-1.33%69 710
HOYA CORPORATION22.25%57 064
DEXCOM, INC.50.53%53 217
SARTORIUS STEDIM BIOTECH61.16%50 552